테네시의 다발성 골수종 임상 시험
다발성 골수종 관련 연구 32개가 테네시 내 여러 지역에서 참여자를 모집하고 있습니다.
테네시의 도시
공식 연구 텍스트(영어)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Nashville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT07391657A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Sarah Cannon Research Institute, Nashville
피험자 모집 중4상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT05201781A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- SCRI Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07258511A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Henry-Joyce Cancer Clinic, Nashville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT05552222A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
- Research Site, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07073547A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Tennessee Oncology, PLLC, Nashville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07518186A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- Sarah Cannon Research Institute, Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT07116616TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute, Nashville
피험자 모집 중2상
12세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT02693535A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- SCRI Oncology Partners /ID# 278353, Nashville
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07095452Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Tennessee Oncology, Nashville
- Vanderbilt University Medical Center, Nashville
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT06297226A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
- SCRI Oncology Partners, Nashville
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 4. 업데이트됨 · NCT07637578Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Tennessee Oncology, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 28. 업데이트됨 · NCT06375044A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 27. 업데이트됨 · NCT07681596A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Nashville
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT07227311MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Ascension St. Thomas Hospital, Nashville
- Tennessee Oncology, PLLC - Investigational Drug Services, Nashville
- Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Center for Blood Cancers, Nashville
- 외 2개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 8. 24. 업데이트됨 · NCT06152575A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Chattanooga
- GSK Investigational Site, Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 19. 업데이트됨 · NCT05714839Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing
- Vanderbilt University Medical Center, Nashville
피험자 모집 중2상
18세 ~ 70세 · 모든 성별 · 2026. 8. 19. 업데이트됨 · NCT07485647A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- SCRI Oncology Partners, Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 18. 업데이트됨 · NCT06292780A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Tennessee Oncology, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 18. 업데이트됨 · NCT05651932AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Nashville
- Research Site, Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 17. 업데이트됨 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Nashville
- Research Site, Nashville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 8. 14. 업데이트됨 · NCT07764978A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Tennessee Oncology, Nashville
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 8. 6. 업데이트됨 · NCT07284758A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Tennessee Oncology, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 16. 업데이트됨 · NCT06121843A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Baptist Memorial Hospital /ID# 280677, Memphis
- Vanderbilt Ingram Cancer Center /ID# 252470, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 13. 업데이트됨 · NCT05650632Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- SCRI Oncology Partners, Nashville
피험자 모집 중2상
19세 이상 · 모든 성별 · 2026. 6. 4. 업데이트됨 · NCT06974786Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Vanderbilt-Ingram Cancer Center (VICC), Nashville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 6. 4. 업데이트됨 · NCT05243797Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- TriStar Bone Marrow Transplant, Nashville
- Vanderbilt- Ingram Cancer Center, Nashville
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 4. 22. 업데이트됨 · NCT05972135A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- TriStar Centennial Medical Center, Nashville
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 3. 24. 업데이트됨 · NCT04988555A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- Local Institution - 0008, Nashville
- Tennessee Oncology, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 3. 18. 업데이트됨 · NCT06153251cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist (BHMCC), Memphis
- Vanderbilt-Ingram Cancer Center, Nashville
피험자 모집 중관찰 연구건강한 지원자 환영
40세 이상 · 모든 성별 · 2026. 1. 20. 업데이트됨 · NCT05366881CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- Tennessee Oncology, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2025. 9. 25. 업데이트됨 · NCT05722418IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- SCRI Oncology Partners, Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2025. 6. 3. 업데이트됨 · NCT06119685ClinicalTrials.gov 출처, 2026. 9. 30. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.